Rs 6 Dividend Alert: Healthcare Stock Eyes Breakout Above Rs 2,850 — Record Date In June; Ready For A Rally?

In India, Dr. Lal PathLabs offers diagnostic testing as well as associated healthcare services to patients and healthcare practitioners for use in core testing, patient diagnosis, and the prevention, monitoring, and treatment of diseases and other ailments. The organization has 6,607 Patient Service Centers (PSCs), 12,365 Pick-up Points (PUPs), and 298 clinical laboratories as of March 31, 2025 (including the National Reference Lab in Delhi and the Regional Reference Lab in Kolkata, Bangalore, and Mumbai). Following the release of the company's financial results for the quarter and fiscal year ending March 31, 2025, as well as the final dividend for FY25, Dr. Lal PathLabs' shares closed Friday's trading session on the NSE 1.39% higher at Rs 2,827 per share, with a market capitalization of Rs 23,631.38 Cr.

Lal Path Labs Dividend

The Board of Directors considered and approved the "Recommendation of final dividend of INR 6/- per equity share (@ 60% on a face value of INR 10/- each) for the financial year ended March 31, 2025, subject to approval of the Members of the Company at ensuing Annual General Meeting ("AGM"). The record date for the purpose of payment of final dividend shall be June 06, 2025. The Final Dividend will be dispatched/ credited within 30 days of the approval by the Members," said Lal Path Labs in a stock exchange filing.

Lal Path Labs Q4 Results

On a consolidated basis, the company reported a net revenue of Rs 603 Cr in the quarter ended in March 2025 up by 10.5% YoY from Rs 545 Cr in the same quarter of the previous fiscal year, whereas for the full year ended FY25 its revenue reached Rs 2461 Cr compared to Rs 2227 Cr in FY24 representing a growth of 10.5%. The company's EBITDA stood at Rs 169 Cr in Q4FY25, up by 16.9% YoY from Rs 145 Cr in Q4FY24, whereas in FY25, the EBITDA stood at Rs 696 Cr, up by 14.2% from Rs 609 Cr in FY24.

The company reported a consolidated net profit of Rs 156 Cr in Q4FY25, up by 81.4% YoY from Rs 86 Cr in Q4FY24, whereas for the entire year FY25, the net profit stood at Rs 492 Cr, up by 35.9% from Rs 362 Cr in FY24.

Lal Path Labs Share Price Target

"The stock is showing signs of recovery with higher lows and improving momentum. A sustained move above ₹2850 could take it toward ₹2900-₹2950. Support is placed near ₹2750. RSI is turning bullish, suggesting further upside. Overall, the trend looks positive, and buying on dips near support levels may offer good risk-reward opportunities," commented Riyank Arora - Technical Analyst - Mehta Equities Limited.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.